Elucidating the specific pharmacological mechanism of action (MOA) of Normally transpiring compounds can be challenging. While Tarselli et al. (sixty) developed the first de novo artificial pathway to conolidine and showcased that this In a natural way developing compound correctly suppresses responses to both of those chemically induced and inflam